fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

GLP-1 RA drugs effectively treat obesity in adults without diabetes

Written by | 7 Jan 2025

A meta- analysis of studies evaluating the efficacy and safety of various glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for treating obesity in adults without diabetes, suggests… read more.

NICE (UK) positive for Zepbound (tirzepatide) for managing overweight and obesity – Eli Lilly

Written by | 6 Jan 2025

NICE (UK): 1.1 Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have:… read more.

FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity – Eli Lilly

Written by | 26 Dec 2024

Eli Lilly and Company announced the FDA approved Zepbound (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound… read more.

Tirzepatide shows powerful diabetes-prevention effect in three-year trial

Written by | 2 Dec 2024

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a… read more.

AHA 2024 – Tirzepatide lowers the risk of worsening heart failure and CVD death for obese adults

Written by | 20 Nov 2024

Researchers from the SUMMIT trial have reported that treatment with tirzepatide has reduced the risk of worsening heart failure and cardiovascular disease-related  death for obese adults. The findings… read more.

Tirzepatide associated with greater weight loss in women than men

Written by | 1 Oct 2024

All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced… read more.

Semaglutide and tirzepatide treatment leads to weight loss in type 1 diabetes

Written by | 14 Sep 2024

Treatment with semaglutide and tirzepatide led to significant weight loss and improved blood sugar control in overweight or obese patients with type 1 diabetes (T1D). Researchers reported this… read more.

New weight loss medication may help lower blood pressure in adults with obesity

Written by | 5 Feb 2024

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took… read more.

Zepbound (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks – Eli Lilly

Written by | 16 Dec 2023

Detailed results from SURMOUNT-4, which showed Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related… read more.

Tirzepatide enhances weight loss with sustained treatment but discontinuation leads to weight regain

Written by | 15 Dec 2023

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine… read more.

CHMP positive for Mounjaro (tirzepatide) for the treatment of obesity – Eli Lilly

Written by | 16 Nov 2023

Eli Lilly’s Mounjaro is recommended for use in Europe for the treatment of obesity. The recommendation comes the same week the drug was approved for obesity treatment in… read more.

FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors – Eli Lilly

Written by | 11 Nov 2023

The FDA approved Eli Lilly and Company’s Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.